Defective CD2 pathway T cell activation in systemic lupus erythematosus

Area of Science:

• Immunology
• Cellular Biology
• Autoimmune Diseases

Background:

• CD2 is a surface molecule crucial for an antigen-independent pathway of human T cell activation.
• This CD2 pathway may play a role in thymocyte differentiation, preceding T cell receptor complex development.
• Impaired T cell regulation is observed in systemic lupus erythematosus (SLE), necessitating investigation into T cell activation pathways.

Purpose of the Study:

• To investigate the activation of peripheral blood lymphocytes via the CD2 pathway in SLE patients compared to healthy controls.
• To determine if SLE patients exhibit altered T cell responses to anti-CD2 antibodies.
• To explore potential contributing factors to observed T cell dysfunction in SLE.

Main Methods:

• Peripheral blood lymphocytes from 57 SLE patients and 32 healthy controls were stimulated with anti-CD2 antibodies.
• T cell activation responses were measured.
• Experiments included co-addition of phorbol myristate acetate and removal of non-T cells to assess normalization of responses.

Main Results:

• SLE patients demonstrated significantly lower CD2 pathway responses compared to controls (P < 0.0001).
• A subset of SLE patients (18/57) exhibited responses below the range of all controls.
• Low responses in some SLE patients were normalized by phorbol myristate acetate or removal of non-T cells.

Conclusions:

• Certain SLE patients exhibit impaired T cell activation through the CD2 pathway.
• This impairment may stem from intrinsic T cell defects.
• Non-T cell regulatory influences could also contribute to the observed T cell dysfunction in SLE.